Sign Up
OverviewAPI
The popularity of GLP-1 agonists, such as Wegovy and Ozempic, was a hot topic during Q3 earnings calls. Retail investors have been rushing to buy Eli Lilly's stock after its weight-loss drug Zepbound received approval. Medical-device investors are rebounding after revised data on obesity drugs provided positive results. Weight-loss drugs are dividing investors on medical device stocks, with concerns about the potential impact on diabetes-related device makers.

Ask a question